Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens

Mutation Research - Reviews in Genetic Toxicology

Volumn 365, Issue 1-3, 1996, Pages 119-127

  Tennant, Raymond W ^a   Spalding, Judson ^a   French, John E ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

bioassay model; carcinogenesis; p53 heterozygote; Tg AC; transgenic mouse

Indexed keywords

ACRYLAMIDE DERIVATIVE; ACRYLIC ACID ETHYL ESTER; BENZENE; CARCINOGEN; RESERPINE; TRIETHANOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIOASSAY; CARCINOGEN TESTING; CARCINOGENESIS; FEMALE; HETEROZYGOTE; MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS;

EID: 0029855293     PISSN: 01651110     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1110(96)90016-0     Document Type: Article

References (36)

1. Adams J.M., Cory S. Transgenic models of tumor development. Science. 254:1991;1161-1167.
2. Bishop J.M. Molecular themes in oncogenesis. Cell. 64:1991;235-248.
3. Christofori G., Hanahan D. Molecular dissection of multi-stage tumorigenesis in transgenic mice. Semin. Cancer Biol. 5:1994;3-12.
4. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A.J., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to sponetaneous tumors. Nature. 356:1992;215-221.
5. Drinkwater N.R. The interaction of genes and hormones in hepatocarcinogenesis. Cockburn A., Smith L. Nongenotoxic Carcinogenesis. 1994;219-230 Springer Verlag, Berlin.
6. Finlay C.A., Hinds P.W., Levine A.J. The p53 protooncogene can act as a suppressor of transformation. Cell. 57:1989;1083-1093.
7. Hansen L., Tennant R.W. Focal transgene expression associated with papilloma development in v-Ha-ras transgenic TG · AC mice. Mol. Carcinogen. 9:1994;143-156.
8. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell. 71:1992;543-546.
9. Harvey M., McArthur M.J., Montgomery C.A.J., Bradley A., Donehower L.A. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 7:1993a;938-943.
10. Harvey M., McArthur M.J., Montgomery C.A.J., Butel J.S., Bradley A., Donehower L.A. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nature Genet. 5:1993b;225-229.
11. Haseman J.K. Data analysis: statistical analysis and use of historical control data. Regul. Toxicol. Pharmacol. 21:1995;52-59.
12. Haseman J.K., Johnson F.M. Analysis of National Toxicology Program rodent bioassay data for anticarcinogenic effects. Mutation Res. 350:1996;131-141.
13. Hennings H., Glick A.B., Lowry D.T., Krsmanovic L.S., Sly L.M., Yuspa S.H. FVB/N mice: an inbred strain sensitive to the chemical induction of squamous cell carcinomas of the skin. Carcinogenesis. 14:1993;2353-2358.
14. Huff J.E., Haseman J.K., Demarini D.M., Eustis S., Maronpot R.R., Peters A.C., Persing R.L., Crisp C.E., Jacobs A.C. Multiple-site carcinogenicity of benzene in Fischer 344 rats and B6C3F1 mice. Environ. Health Perspect. 82:1989;125-163.
15. Kastan M.B., Zhan Q., el-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.J.J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
16. Kemp C.J., Donehower L.A., Bradley A., Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell. 74:1993;813-822.
17. Kemp C.J., Wheldon T., Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nature Genet. 8:1994;66-69.
18. Leder A., Kuo A., Cardiff R.D., Sinn E., Leder P. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: Efects of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. USA. 87:1990;9178-9182.
19. Levine A.J. The p53 tumor suppressor gene and gene product. Princess Takamatsu Symp. 20:1989;221-230.
20. Mahler J.F., Mann P., Takaoka M., Maronpot R.M. Spontanous lesions of the FVB/N mouse. Toxicol. Pathol. 23:1995;744-745.
21. Merlino G. Regulatory imbalances in cell proliferation and cell death during oncogenesis in transgenic mice. Semin. Cancer Biol. 5:1994;13-20.
22. Mirsalis J.C., Monforte J.A., Winegar R.A. Transgenic animal models for measuring mutations in vivo. Crit. Rev. Toxicol. 24:1994;255-280.
23. NCI/NTP. Bioassay of p-cresidine for possible carcinogenicity. 1979;NCI.
24. NTP. Carcinogenesis studies of ethyl acrylate (CAS No. 140-88-5) in F344/N Rats and B6C3F1 mice (gavage studies). 1986;National Toxicology Program, Research Triangle Park, NC.
25. NTP. Toxicology and carcinogenesis studies of 4-vinyl-1-cyclohexene diepoxide in F344/N rats and B6C3F1 mice. 1989a;National Toxicology Program, Research Triangle Park, NC.
26. NTP. Toxicology and carcinogenesis studies of N-methyl-oacrylamide in F344/N rats and B6C3F1 mice. 1989b;National Toxicology Program, Research Triangle Park, NC.
27. Spalding J.W., Momma J., Elwell M.R., Tennant R.W. Chemical induced skin carcinogenesis in a transgenic mouse line (TG · AC) carrying a v-Ha-ras gene. Carcinogenesis. 14:1993;1335-1341.
28. Storer R.D., Cartwright M.E., Cook W.O., Soper K.A., Nichols W.W. Short-term carcinogenesis bioassay of genotoxic procarcinogens in PIM transgenic mice. Carcinogenesis. 16:1995;285-293.
29. Tennant R.W., Ashby J. Classification according to chemical stucture, mutagenicity to Salmonella and level carcinogenicity of a future 39 chemicals tested for carcinogenicity by the U.S. National Toxicology Program, Mutation Res. 257:1991;209-227.
30. Tennant R.W., Stasiewicz S., Spalding J. Comparison of multiple parameters of rodent carcinogenicity and in vitro genetic toxicity. Environ. Mutagen. 8:1986;205-227.
31. Tennant R.W., Rao G.N., Russfield A., Seilkop S., Braun A.G. Chemical effects in transgenic mice bearing oncogenes expressed in mammary tissue. Carcinogenesis. 14:1993;29-35.
32. Tennant R.W., French J.E., Spalding J.W. Identification of chemical carcinogens and assessing potential risk in short term bioassays using transgenic mouse models. Environ. Health Perspect. 103:1995;942-950.
33. Viney J.L. Transgenic and gene knockout mice in cancer research. Cancer Metastasis Rev. 14:1995;77-90.
34. Weinberg R.A. Oncogenes and tumor suppressor genes. Ca. Cancer J. Clin. 44:1994;160-170.
35. Weinberg R.A. The molecular basis of oncogenes and tumor suppressor genes. Ann. NY Acad. Sci. 758:1995;331-338.
36. Zambetti G.P., Levine A.J. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 7:1993;855-865.